Stereotaxis (STXS) opened Q1 2026 with revenue of US$6.3 million and a net loss of US$6.2 million, equal to an EPS loss of US$0.06, as the stock trades around US$1.85. The company reported quarterly revenue of US$7.5 million in Q1 2025 and US$6.3 million in Q1 2026, while EPS loss moved from US$0.07 to US$0.06 over the same period. On a trailing twelve month basis, EPS loss was US$0.24 on revenue of US$31.2 million. Overall, the update keeps the focus on how revenue growth potential might offset persistent losses and what that could mean for margins over time.

See our full analysis for Stereotaxis.

With the headline numbers reported, the next step is to see how this earnings profile compares with the main bullish and bearish narratives that have formed around Stereotaxis, and how those views are affected by the latest margins and growth trends.

Losses Stay Near US$6 Million As Revenue Bounces Around

• Over the last four reported quarters, revenue moved between US$6.3 million and US$8.8 million, while quarterly net losses stayed in a fairly tight range around US$4.1 million to US$7.8 million, with Q1 2026 showing a net loss of US$6.2 million on US$6.3 million of revenue.
• Consensus narrative expects that expanding products like GenesisX and MAGiC catheters can eventually support better margins, yet the trailing twelve month loss of US$22.9 million against US$31.2 million of revenue keeps that bullish view very dependent on the company proving it can do more with each dollar of sales.
  • Supporters point to higher margin proprietary products and a growing installed base as potential drivers of operating leverage, but the recent quarters still show sizeable losses close to Q1 2026 levels.
  • The focus on multi application platforms and digital tools like Synchrony and SynX aims to deepen recurring revenue, while the current results highlight that this thesis is still mainly reflected in forecasts rather than in reported profitability.

On these numbers, bulls are effectively betting that the current loss profile can shift meaningfully as higher margin products scale, not that the business is already there today 🐂 Stereotaxis Bull Case.

Cash Runway Under One Year With Ongoing Losses

• The trailing twelve month net loss of US$22.9 million against a flagged cash runway of under 12 months means the company is currently consuming cash faster than its recent revenue base of US$31.2 million would suggest is comfortable.
• Bears highlight the combination of continued losses and a short cash runway as a key risk, and the latest figures do align with that concern.
  • Losses have reportedly grown at about 17.1% per year over the past five years, which, together with the current loss level, supports the view that external funding could remain important.
  • Concerns that hospital approval cycles and capital equipment sales are slow to convert into steadier cash flows are echoed by the fact that recent quarters, including Q1 2026, do not yet show any move to profitability.

For anyone focused on capital risk, the combination of under one year of cash runway and a trailing loss near US$23 million is exactly what the cautious camp is watching 🐻 Stereotaxis Bear Case.

Premium 5.8x P/S Versus Industry With US$4.13 Target

• The stock trades at a P/S of 5.8x compared with 2.7x for the US Medical Equipment industry and about 5.1x for peers, while analysts cited in the data group around a price target of US$4.13, versus the current share price of US$1.85.
• Supporters of the bullish narrative argue that forecast revenue growth of about 30.7% per year can justify this premium multiple, but the same data notes that profitability is not expected over the next three years, which means the valuation rests heavily on revenue growth and future margin improvement rather than current earnings.
  • The implied upside from US$1.85 to the US$4.13 target is large in percentage terms, yet it is paired with a business that currently reports a loss making EPS on both a quarterly and trailing twelve month basis.
  • Critics point out that paying a premium to the broader industry on P/S while the company remains loss making and reliant on external funding leaves little room if revenue or margins fail to track those growth expectations.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Stereotaxis on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment clearly split between the risks of ongoing losses and the potential rewards tied to revenue and margins, it makes sense to look through the underlying data yourself and decide how comfortable you are with that balance, starting with the 2 key rewards and 2 important warning signs.

See What Else Is Out There

Stereotaxis is still reporting sizeable losses near US$6 million a quarter, with a cash runway under 12 months and no clear path to profitability yet.

If that mix of ongoing losses and cash strain makes you uneasy, it is worth balancing your watchlist with companies featured in the 68 resilient stocks with low risk scores that prioritize resilient earnings and stronger financial footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.